• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 25th October 2012

Tracking Changes in the Causes of Death in England and Wales

OHE’s health and health care statistics service long has been respected as a source of reliable data. In an OHE Briefing just published, OHE uses this data to take a closer look at what has been responsible for changes in…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Causes of Death: A Study of a Century of Change in England and Wales

OHE’s health and health care statistics service long has been respected as a source of reliable data. In an OHE Briefing just published, OHE uses this data to take a closer look at what has been responsible for changes in the causes of death in England and Wales.

Causes of Death: A Study of a Century of Change in England and Wales

OHE’s health and health care statistics service long has been respected as a source of reliable data.  In an OHE Briefing just published, OHE uses this data to take a closer look at what has been responsible for changes in the causes of death in England and Wales.

We are living longer. In his well-known research, Thomas McKeown found that life expectancy in England and Wales increased by around 30 years between 1901 and 1971. He attributed that primarily to a reduction in deaths from infectious diseases, the result of improvements in nutrition, safer water and better sanitation, and changes in personal behaviour.

This new OHE Briefing, which extends McKeown’s analysis to 2007, finds that mortality continued to decline after 1971. It tells a different story, however, about changes in the causes of death. Between 1971 and 2007, only about 20% of the reduction in age-standardised mortality rates in England and Wales is attributable to reductions in infectious diseases. This in part is because some illnesses have all but disappeared—for example, cholera, diarrhoea, dysentery and respiratory tuberculosis[1].  But it is due mainly to marked declines in deaths from other causes.

It is striking that almost 20% of the decline in mortality during 1971-2007 is the result of lower age-standardised mortality rates for just one cause of death—cardiovascular disease.  This is despite an increase in incidence rates for that disease. Innovation in health care has been important; for example, the first beta blocker was marketed in the UK in 1965, offering the first truly effective medical treatment for the disease. The authors note, however, that other factors that also have had an important effect, including lifestyle changes.

The OHE Briefing highlights some diseases for which age-standardised mortality rates in recent years have risen. For example, between 1997 and 2007, mortality rates increased for diseases of the digestive system, including fibrosis and cirrhosis of the liver. According to the authors, “This may indicate that whereas, in the past, changes in sanitation and other public factors outweighed effects from personal behaviours, in the current day negative personal behaviours can increase the risk for both morbidity and mortality from certain diseases (e.g. obesity and diabetes)”.

At the same time that life expectancy has increased, so has the number of individuals living with chronic disease. Not surprisingly, the percentage of the population reporting chronic ill health has increased the most for those aged 65 and over—from 53% in 1972 to 63% in 2007.

Both declines in mortality and increases in morbidity will have important implications for health and health care for many decades to come.

Download Baillie, L. and Hawe, E. (2012) Causes of death: A study of a century of changes in England and Wales. 53. OHE Briefing. London: Office of Health Economics.

 


[1] OHE’s first publication, in 1962, focused on tuberculosis and the challenges of conquering it. For an overview of that and a more recent, 1996, publication by OHE, click here.  

 

  • Health Care Systems
  • Economics of Innovation
  • Briefing

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • June 2020

OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!